Preparation and LC/MS Analysis of Oligonucleotide Therapeutics from Biological Matrices

Bioanalytical

Preparation and LC/MS Analysis of Oligonucleotide Therapeutics from Biological Matrices

24 Mar, 2011

Published over 15 years ago. See the latest and most current information on Bioanalytical.

James Rudge, Greg Scott, Mark Hail, and Michael McGinley
1 min read
Download

Due to their association with other biomolecules as well as their unique chemical properties, oligonucleotide therapeutics present unique challenges in their isolation and LC/MS analysis from biological matrices. A new isolation protocol using a mixed-mode SPE cartridge is presented that demonstrates high recovery and sensitivity into the low ng/mL range. Optimization of LC/MS mobile phase conditions as well as MS analysis parameters results in improved sensitivity and identification of oligonucleotides and their metabolites.

Introduction

Therapeutic uses of oligonucleotides are becoming an increasingly popular approach to treat disease. Since the human genome was fully decoded back in 2003, researchers are gaining a rapid and comprehensive understanding of which genes code for which processes in normal human physiology. Gaining knowledge of what is normal has allowed scientists to identify abnormalities in genes which lead to disease states. Such abnormalities manifest in the incorrect coding of proteins which then leads to downstream problems with cell physiology.

Latest Articles

Explore Our Other Sites

Labmate Online
Fungal and bacterial triggers may be drivers in steroid-resistant asthma
Explore more Arrow
Envirotech Online
New oxygen sensor range targets OEM gas detection applications
Explore more Arrow
Pollution Solutions Online
Skid-mounted systems target oxygen and moisture removal for renewable natural gas
Explore more Arrow
Petro Online
Automated freezing-point testing arrives for jet fuel: what ASTM D8615 changes for lab workflows
Explore more Arrow